Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-dNPM1-TCR.1 in Relapsed or Refractory NPM1-mutated AML
NCT06424340Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-dNPM1-TCR.1 in acute myeloid leukemia (AML), sponsored by Miltenyi Biomedicine GmbH. Started Aug 2024; status: recruiting.
02
Drugs
MB-dNPM1-TCR.1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06424340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424340.